SUCLG2 and acute myeloid leukemia: CD34+ stem/progenitor cells from FLT3-ITD+ AML patients displayed higher ETC complex II activity compared to FLT3-wt AMLs (Fig. 1f), which correlated with SDHA, SDHB, and SUCLG2 protein expression (Fig. 1g).